Heart1.com: Great Information, Real Community, Better Living.
 Register
 Login
 Main Page
 Heart News
Feature Story
 Education Center
Conditions
Procedures
Diagnostics
 Heart Attack Center
Prevention
Survivors
Dr. Tod Engelhardt  Heart
 Hero™

Dr. Tod Engelhardt:
Combating Major Blood Clots.
About Heroes
 Join the Discussion  in  Our Forums
 Community
Heart1 Forums
Patient Stories
 Reference
Online Resources
Video Library
advertisement
Search the Body1 Network
May 23, 2019  
HEART NEWS: Feature Story

  • Print this Article
  • Email this Article
  • Links/Reprints
  • Stroke and Heart Attack Prevention

    Major advance in stroke and heart attack prevention


    July 31, 2002
    Two new reports show that the cholesterol-lowering drugs known as statins
    are both safer and more effective at reducing deaths from heart attack and
    stroke than previously thought, findings that are likely to expand the use
    of these already widely prescribed medications.

    British researchers reported recently that simvastatin (marketed in the
    United States as Zocor) reduced heart attacks, stroke, and the need for
    invasive heart procedures, such as angioplasty, by 25 percent. Like
    previous research, the study also found that deaths from all causes were
    significantly cut by statin use. But where the British study of more than
    20,000 people breaks new ground is in demonstrating a significant reduction
    in mortality among high-risk people who have normal or low blood
    cholesterol levels.

    "It's a blockbuster study that shows statins bring benefit to
    higher-risk patients and to groups who might not have been considered
    candidates for therapy," says Sidney Smith, chief science officer for the
    American Heart Association.

    That, in turn, is likely to change "the rule book on statin
    prescribing," notes Richard Horton, editor of The Lancet, which published
    the report, known as the Heart Protection Study. Experts say the British
    findings could make statins as routine as aspirin for high-risk people -
    those who have diabetes, have had a heart attack or stroke, or undergone
    angioplasty or bypass surgery - even if they have normal or even low levels
    of the most damaging form of cholesterol, low-density lipoprotein
    (LDL).

    The findings "are the most important and far-reaching results for the
    treatment and prevention of heart disease and stroke that we have seen in a
    generation," Horton says.

    Publication of the Heart Protection Study comes right after a joint
    committee of the American Heart Association, the American College of
    Cardiology and the federal government's National Heart, Lung, and Blood
    Institute (NHLBI) concluded that the five statin drugs on the market are
    safe and effective for the majority of patients. The committee was formed
    last year to review statins after the voluntary withdrawal from the market
    of Baycol - at the time one of the most widely prescribed statins in the
    United States.

    "The bottom line is that when statins are given properly and monitored
    appropriately, they can do a tremendous amount to reduce cardiac risk in
    our patients," said Richard C. Pasternak, director of preventive cardiology
    at Massachusetts General Hospital in Boston and chairman of the committee
    that wrote the review.

    Since 1987, when the Food and Drug Administration approved the first
    statin drug - lovostatin - the market for this group of
    cholesterol-lowering drugs has grown widely. The NHLBI estimates that 36
    million people in the United States are candidates for statins. In 2000,
    two statins - atorvastatin and simvastatin - ranked second and fourth among
    the top 10 prescription drug sales in the United States.

    Despite their popularity, the new report notes that their potential use
    "has not been fully realized because many patients at heightened risk are
    not being treated with these drugs."

    The reluctance to use statins is partly fueled by cost and partly by
    safety concerns.

    "There's still a lot of distrust about taking drugs," says Margo Denke,
    professor of medicine at the University of Texas Southwestern Medical
    School in Dallas and a member of an NHLBI committee that in 2001 set
    guidelines for cholesterol treatment. "A lot of people say to me, 'Let me
    first try losing weight.' But it's very hard to be disciplined enough to
    stick with a weight-loss program."

    And once someone has been identified at risk, "it's important to bite
    the bullet and take the statins," Denke says. "Besides, maybe paying for
    the drug will get you to get your rear end out there and move and do
    something about losing weight." (Statins cost about $50 to $115 per month,
    depending on the dose. Health insurance will often cover part of the cost,
    but many people pay a co-payment of at least $15 per 30-day
    prescription.)

    Behavioral changes - giving up smoking, improving diet, daily exercise,
    achieving a healthy body weight - remain the cornerstone of heart disease
    prevention, even for those taking statins.

    Cholesterol-lowering drugs "are meant to be an adjunct to lifestyle
    changes such as diet and exercise," Smith says. "I am very concerned by
    patients and a society that turns rapidly to medications without first
    understanding that changing lifestyle has to be the foundation of
    prevention."

    What the latest research demonstrates is the safety and effectiveness of
    these medications for a wider range of patients. "Should we rethink statin
    use?" asks David Gordon, special assistant for clinical studies at the
    NHLBI's division of heart and vascular disease. "Current recommendations
    are to go for a goal of an LDL less than 100 milligrams." The newest
    findings suggest, he says, that regardless of LDL levels, statins ought to
    be used as part of the "routine" prevention in people with known heart
    disease or in those with a very high risk of coronary disease.

    That's because the five statins that remain on the market received a
    clean bill of health from the clinical guidelines committee, whose findings
    appear in the latest issue of the Journal of the American College of
    Cardiology (www.acc.org). The problem of kidney failure, which sidelined
    Baycol, occurs in only about one in every million users of other statins,
    the report found.

    Even with Baycol, nearly all the 31 deaths linked to its use occurred in
    frail people, 80 years and older, who had multiple health problems. And the
    large-scale British study showed no deaths from kidney failure.

    As Gordon notes, "the average person who takes [statins] probably has
    very little chance of getting" kidney failure. Even so, experts urge statin
    users to notify their doctors immediately if they experience muscle pain or
    darkened urine - symptoms that could lead to kidney failure.

    While statins "are safe drugs, as safe as aspirin," says C. Noel
    Bairey-Merz, a member of the committee that drafted the clinical
    guidelines, "there is no such thing as a free lunch."




    Last updated: 31-Jul-02

    Comments

  • Add Comment
  •    
    Interact on Heart1

    Discuss this topic with others.
     
    Feature Archives

    Heart Disease Patients Need to Exercise to Benefit from the Protective Effects of Wine

    Effective Treatment for Heart Failure Possible Following Discovery of Heart Molecule

    Significant Decrease in Heart Disease after Prison Smoking Bans

    Heart Failure Patients Who Sleep Poorly Are at Double the Risk for Hospitalization

    Long-Term Survival Possible for Pediatric Heart Transplant Patients

    Next 5 Features ...

    More Features ...
       
     
     
    Related Content
    Aspirin’s Heart Benefits Differ by Gender

    Statin Therapy

    Cholesterol Drug May Help Clogged Arteries

    Healthy Hearts: Keeping The Beat

    Childhood Depression Linked To Cardiac Risks Later In Life

    More Features ...
     
    Home About Us Press Jobs Advertise With Us Contact Us
    advertisement
    © 2019 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.